CDK12, a cyclin-dependent kinase that directly regulates transcription and controls genomic stability, has been linked to poor prognosis in prostate cancer patients for whom both CDK12 alleles are inactivated, particularly in response to taxane and hormonal therapies (37, 38). The gene discussed is CDK12; the disease is prostate carcinoma.